Target validation in drug discovery /

This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug develo...

Full description

Bibliographic Details
Corporate Author: ScienceDirect (Online service)
Other Authors: Metcalf, Brian W., Dillon, Susan, 1952-
Format: eBook
Language:English
Published: Amsterdam ; Boston : Academic Press, [2007]
Subjects:
Online Access:Connect to the full text of this electronic book
Publisher description

MARC

Tag First Indicator Second Indicator Subfields
LEADER 00000cam a2200000Ia 4500
001 in00002425989
005 20190327171449.0
006 m d
007 cr cn|||||||||
008 070802s2007 enka sb 001 0 eng d
020 |a 9780123693938 
020 |a 0123693934 
035 |a (OCoLC)ocn162130366 
035 |a (OCoLC)162130366 
037 |a 113098:113186  |b Elsevier Science & Technology  |n http://www.sciencedirect.com 
040 |a OPELS  |c OPELS  |d UtOrBLW 
049 |a TEFA 
050 1 4 |a RM301.63  |b .T36 2007eb 
060 1 4 |a 2006 N-124 
060 1 4 |a QV 744  |b T185 2007 
082 0 4 |a 615/.19  |2 22 
245 0 0 |a Target validation in drug discovery /  |c editors, Brian W. Metcalf and Susan Dillon. 
264 1 |a Amsterdam ;  |a Boston :  |b Academic Press,  |c [2007] 
264 4 |c ©2007 
300 |a xii, 279 pages :  |b illustrations ;  |c 27 cm. 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
533 |a Electronic reproduction.  |b Amsterdam :  |c Elsevier Science & Technology,  |d 2007.  |n Mode of access: World Wide Web.  |n System requirements: Web browser.  |n Title from title screen (viewed on July 25, 2007).  |n Access may be restricted to users at subscribing institutions. 
520 |a This work presents a comprehensive contemporary framework for approaching target validation in drug discovery. It begins with a detailed description of new enabling technologies, including aptamers, RNA interference, functional genomics, and proteomics. The next section looks at biologic drug development with in-depth discussion of lessons learned from such well-known cases as Erbitux, Herceptin, and Avastin. Additional targets known as "second generation" drugs, which can be identified when disease pathways are validated by biologics, present new possible small molecule therapeutics and serve as the focus of the final section of the book. 
505 0 |a Section Contents -- I. Pharmaceutical Biotechnology for Target Validation -- II. Target Validation for Biopharmaceutical Drug Discovery -- III. Validating Targets of Small Molecule Approaches. 
504 |a Includes bibliographical references and index. 
500 |a Electronic resource. 
650 0 |a Drug development. 
650 0 |a Drugs  |x Testing. 
650 0 |a High throughput screening (Drug development) 
650 1 2 |a Drug Design. 
650 2 2 |a Drug Delivery Systems. 
650 2 2 |a Technology, Pharmaceutical. 
650 6 |a Médicaments  |x Développement. 
650 6 |a Médicaments  |x Essais cliniques. 
650 6 |a Criblage à haut débit (Développement des médicaments) 
655 7 |a Electronic books.  |2 local 
700 1 |a Metcalf, Brian W. 
700 1 |a Dillon, Susan,  |d 1952- 
776 1 |c Original  |z 0123693934  |z 9780123693938  |z 9780123693938  |w (DLC) 2006049868  |w (OCoLC)70823305 
710 2 |a ScienceDirect (Online service) 
856 4 0 |u http://proxy.library.tamu.edu/login?url=http://www.sciencedirect.com/science/book/9780123693938  |z Connect to the full text of this electronic book  |t 0 
856 4 2 |3 Publisher description  |u http://www.loc.gov/catdir/enhancements/fy0664/2006049868-d.html  |t 0 
994 |a C0  |b TEF 
999 |a MARS 
999 f f |s 0416c194-846f-3529-844e-93b98493001f  |i c916ae23-fd33-393c-ba04-a0a9cdfbb5a5  |t 0 
952 f f |a Texas A&M University  |b College Station  |c Electronic Resources  |d Available Online  |t 0  |e RM301.63 .T36 2007eb  |h Library of Congress classification 
998 f f |a RM301.63 .T36 2007eb  |t 0  |l Available Online